Business
Business and trading update
Business and trading update.
About this update from Ixico Plc
[{"type":"text","content":"\n \nRNS Number : 6903V IXICO plc 17 December 2013 \n \n\n17 December 2013\n \nIXICO plc\nBusiness and trading update\nAssessa™ launched; trading remains on budget\n \nIXICO plc (Ticker: IXI) (\"IXICO\" or the \"Company\"), the brain health company, today announces a business update and includes a trading update for its underlying business, IXICO Technologies Limited (formerly IXICO Limited) for the four and a half months ended 14 October 2013.\n \nHighlights\n· Successful integration of IXICO Technologies Limited and Phytopharm plc and renaming of the enlarged group as IXICO plc\n \n· Launch of Assessa™, our proprietary platform to support timely and accurate diagnosis of dementia\no Widened collaboration with InHealth Limited to provide Assessa™ and complementary services within the UK and Eire\no Initial piloting of Assessa™ in a community setting in collaboration with partners \n \n· Memorandum of understanding signed with Beijing Union Medical and Pharmaceutical General Corporation during the UK trade mission to China following which IXICO has also been awarded its first contract for specialist drug development services with a Chinese pharmaceutical company\n \n· Awarded a new contract to provide clinical trials services by a top fifteen global pharmaceutical company with whom IXICO has not previously worked\no Contract is for early phase clinical trial for an investigational drug for the treatment of mild to moderate Alzheimer's disease\no IXICO has now been awarded contracts by eight of the top fifteen global pharmaceutical companies\n \n· IXICO's work in dementia recognised by Prime Minister David Cameron in his speech to the G8 Dementia Summit on 11 December 2013\n \n· Awarded Stratified Medicine Grant by the Technology Strategy Board, the UK's innovation agency\n \nFinancial Highlights\n· Revenue and expenses in line with budget with the operating loss reflecting planned increased investment to develop Assessa™, the Company's diagnostic platform\n \n· Combined cash deposits of approximately £5.7 million a...